
Fred Cohen
Fred Cohen is a physician-scientist who co-founded Monograph Capital, a life sciences firm, after co-founding TPG Biotechnology and Vida Ventures. He chaired Cell Design Labs when Gilead agreed to buy it for up to $567M in 2017 and sat on the board of Genomic Health, which Exact Sciences bought for $2.5B in 2019.
- Founded
- Monograph Capital, Vida Ventures
- Education
- Stanford University School of Medicine
Track record
Investments Fred Cohen is best known for, with what became of them.
- CCell Design LabsChairman of the boardAcquired by Gilead and Kite for up to $567M in 2017
- GGenomic HealthBoard memberAcquired by Exact Sciences for $2.5B in 2019
- PProgynyBoard memberListed on Nasdaq in 2019
Monograph Capital
Career
- Studied molecular biophysics at Yale, earned a DPhil at Oxford as a Rhodes Scholar and an MD at Stanford.
- Spent about 30 years at UCSF as a professor and chief of endocrinology and metabolism, publishing over 200 papers.
- 2001Co-founded TPG Biotechnology, which invested in over 50 life sciences companies during his 15 years there.
- 2017Co-founded Vida Ventures, a biotechnology investment firm.
- 2017Gilead and Kite agreed to buy Cell Design Labs, which he chaired, for up to $567M.
- 2019Exact Sciences completed its $2.5B purchase of Genomic Health, where he was a director.
- 2021Co-founded Monograph Capital with Charles Conn and became its chairman.
Sources: Yale Ventures — Fred Cohen · Gilead — Gilead and Kite to acquire Cell Design Labs (Dec 2017) · Exact Sciences 10-K FY2019 (Genomic Health purchase price) · Progyny — Board: Fred Cohen · Monograph Capital. Rank: 2026 Strebulaev–Jackson Venture Ranking.
Companies founded


Currently
Active roles, board seats and partnerships.





Education
